Cartesian Therapeutics has entered a strategic licensing agreement with WestGene Biopharma to develop in vivo CAR-T therapies for autoimmune diseases, leveraging WestGene's targeted lipid nanoparticle platform combined with Cartesian's mRNA payload technology. The collaboration aims to initiate a Phase 1 clinical trial in the second half of 2026 for patients with generalized myasthenia gravis, with clinical data expected in the first half of 2027. This partnership could transform autoimmune disease treatment by enabling in vivo delivery of CAR-T therapies, potentially eliminating the need for complex ex vivo manufacturing. Cartesian also plans to advance multiple next-generation anti-BCMA CAR constructs and T-cell engagers using this platform.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Nevada King Gold Corp. received approval from the Bureau of Land Management for its fifth and largest modification to its drilling plan at the Atlanta Gold Mine project in Nevada. This permits 78 additional reverse circulation and 404 rotary air blas...
United Parks & Resorts Inc. announced it will release its second quarter 2026 financial results before the market opens on August 4, 2026. The company will hold a live conference call at 9 a.m. Eastern Time on the same day, accessible via its website...
Alpaca, a brokerage infrastructure startup, secured $435 million in funding to enter prime brokerage services, challenging traditional Wall Street firms. The company’s API supports 94% of US equities and powers tokenized stocks for Kraken. Alpaca’s t...
Raymond James Financial's rating was raised to "Buy" after positive investor event disclosures and a promising preview of its upcoming quarterly results. The company is expected to exceed earnings per share consensus for Q3 FY26, driven by strong per...
